H. Lee Moffitt Cancer Center & Research Institute

Jasper Therapeutics Announces First Patient Dosed in a Phase 1 Trial of Briquilimab in Lower-Risk Myelodysplastic Syndrome

Retrieved on: 
Thursday, June 22, 2023
Neutropenia, Face, Survival, Bone marrow, Quality of life, MDS, Patient, Syndrome, Risk, Conditional sentence, H. Lee Moffitt Cancer Center & Research Institute, B cell, CD117, Therapy, Thrombocytopenia, Safety, Pharmaceutical industry, Jasper

“The initiation of this trial in LR-MDS represents a significant milestone in our briquilimab development program,” said Ronald Martell, President and Chief Executive Officer of Jasper.

Key Points: 
  • “The initiation of this trial in LR-MDS represents a significant milestone in our briquilimab development program,” said Ronald Martell, President and Chief Executive Officer of Jasper.
  • “To date, the potential of briquilimab has been clinically assessed across five transplant indications and we are excited to explore its potential as a treatment option for a chronic disease such as LR-MDS.
  • While certain treatments could be employed to manage the symptoms, they do not typically target diseased cells or offer a comprehensive therapeutic approach.
  • For more information on the Phase 1 trial of briquilimab for the treatment of LR-MDS please visit clinicaltrials.gov and reference identifier: NCT05903274.

Geron to Host Virtual Investor Event on June 14, 2023

Retrieved on: 
Tuesday, June 6, 2023
Biotechnology, FDA, Other Health, Health, Pharmaceutical, Oncology, Other Science, Research, Hospitals, Science, Clinical Trials, Ruxolitinib, Clinic, European Hematology Association, Hematology, Cell therapy, American Society of Clinical Oncology, H. Lee Moffitt Cancer Center & Research Institute, Teaching hospital, Acute myeloid leukemia, ASCO, MDS, Imetelstat, Corporation, Geron Corporation, Risk, EHA, Annual general meeting, Webcast, Society, Pharmaceutical industry

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, will host a virtual investor event on Wednesday, June 14, 2023 at 8:00 a.m. Eastern Time.

Key Points: 
  • Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, will host a virtual investor event on Wednesday, June 14, 2023 at 8:00 a.m. Eastern Time.
  • Topics to be covered at the event include:
    Summary of new IMerge Phase 3 data in lower risk myelodysplastic syndromes (MDS) featured in 2023 medical meetings.
  • This includes presentation of data at the American Society of Clinical Oncology (ASCO) Annual Meeting on June 2, 2023 and upcoming presentations at the European Hematology Association (EHA) Annual Meeting taking place from June 8-11, 2023.
  • An archive of the webcast will be available on the Company’s website for 30 days.

Memgen Announces New Clinical Data on MEM-288 in Advanced/Metastatic NSCLC at ASCO 2023 Annual Meeting

Retrieved on: 
Tuesday, June 6, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, ASCO, American Society of Clinical Oncology, Toxic epidermal necrolysis, H. Lee Moffitt Cancer Center & Research Institute, Necrosis, Toxicity, Patient, NSCLC, Tumor microenvironment, Lung cancer, Society, Apoptosis, Pharmaceutical industry, Medical imaging

Memgen, Inc., a clinical-stage biotechnology company today announced updated clinical data from its first-in-human study of MEM-288, an oncolytic viral therapy, in patients with advanced/metastatic refractory non-small cell lung cancer.

Key Points: 
  • Memgen, Inc., a clinical-stage biotechnology company today announced updated clinical data from its first-in-human study of MEM-288, an oncolytic viral therapy, in patients with advanced/metastatic refractory non-small cell lung cancer.
  • Dr. Andreas Saltos, the lead study investigator at Moffitt Cancer Center, presented the poster presentation at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting in Chicago.
  • Dr. Saltos noted that “We looked at biopsies and blood samples for patients on the study and see encouraging signs of an anti-tumor immune response being generated.
  • Mark Cantwell, Memgen’s CSO, noted, “We continue to follow these patients and implications for expanded avenues to use MEM-288 in combination with multiple therapeutic strategies.”

Reigniting the Cancer Moonshot: Massive Bio Joins CancerX as Founding Member to Accelerate Innovation and AI Implementation in Cancer Care

Retrieved on: 
Sunday, June 4, 2023
Technology, Research, Clinical Trials, Biotechnology, Health, Other Science, Science, Artificial Intelligence, Oncology, Cloud, White House, Partnership, Drug development, SBIR, Clinical trial, Cancer, Intelligence, Toxicity, Multimedia, Movement, ASCO, Cancer Moonshot, Incidence, National Cancer Institute, M&A, H. Lee Moffitt Cancer Center & Research Institute, Patient, Entrepreneurship, Digital, AI, Dime, Pharmaceutical industry, Vaccine

This appointment situates Massive Bio at the forefront of a national public-private partnership aiming to revolutionize the fight against cancer.

Key Points: 
  • This appointment situates Massive Bio at the forefront of a national public-private partnership aiming to revolutionize the fight against cancer.
  • View the full release here: https://www.businesswire.com/news/home/20230604005029/en/
    FINAL CancerX Founding Members Logo Cloud (Graphic: Business Wire)
    As cancer continues to pose a significant global challenge, Massive Bio stands committed to mitigating this scourge.
  • Being chosen as a founding member of CancerX confirms our dedication to advancing precision oncology and democratizing access to groundbreaking cancer treatments.
  • CancerX is primarily focused on advancing digital innovation to improve equity and reduce financial toxicity in cancer care and research.

Roswell Park Study May Provide Clues to Treating Colorectal Cancer More Effectively in Younger Patients

Retrieved on: 
Sunday, June 4, 2023
Roswell Park Comprehensive Cancer Center, American Society of Clinical Oncology, The James Cancer Hospital, Doctor of Philosophy, Oncogene, Incidence, DO, Metabolism, Patient, The Cancer Genome Atlas, Risk, Informatics, Colorectal cancer, Body mass index, H. Lee Moffitt Cancer Center & Research Institute, TCGA, PSA, Prostate cancer, MYC, University, National Cancer Institute, AYA, Research, MS, Cancer, Diagnosis, Growth, BMI, Smoking, PD-L1, Metastasis, Behavior, NRAS, University of Oklahoma Health Sciences Center, Lipid, Cell, Dicarboxylic acid, Ohio State University, CRC, Health informatics, ASCO, Kynurenine, CDT, Gene, Society, Pharmaceutical industry, Birth control, Medical imaging, Upstate New York, MD, Roswell Park

That information could guide the development of new treatments for younger patients, who typically have poorer outcomes.

Key Points: 
  • That information could guide the development of new treatments for younger patients, who typically have poorer outcomes.
  • The team hopes the results of their study will help future studies zero in on new ways of treating colorectal cancer in younger patients.
  • From the world's first chemotherapy research to the PSA prostate cancer biomarker, Roswell Park Comprehensive Cancer Center generates innovations that shape how cancer is detected, treated and prevented worldwide.
  • To learn more about Roswell Park Comprehensive Cancer Center and the Roswell Park Care Network, visit http://www.roswellpark.org , call 1-800-ROSWELL (1-800-767-9355) or email [email protected] .

SOPHiA GENETICS Joins CancerX to Help Accelerate Cancer Research

Retrieved on: 
Friday, June 2, 2023
White House, Office of the National Coordinator for Health Information Technology, Business development, Partnership, Office of the Assistant Secretary for Health, Life, Sophia Genetics, Yale Physician Associate Program, Cancer, Intelligence, Research, Assistant, White, ASCO, Cancer Moonshot, Sophia, Incidence, ONC, Data analysis, H. Lee Moffitt Cancer Center & Research Institute, Machine learning, GENETICS, MSK, Memorial Sloan Kettering Cancer Center, Multi, Digital, Dime, Vaccine, Pharmaceutical industry

BOSTON and LAUSANNE, Switzerland, June 2, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, announced today at ASCO that it has joined as a founding member of CancerX, a new public-private partnership formed to rapidly accelerate the pace of cancer innovation in the United States. As a founding member, SOPHiA GENETICS will help drive the success of CancerX, collaborating to set priorities and practices that will harness the power of innovation to further cancer care and research. SOPHiA GENETICS offers its SOPHiA DDM™ Platform, powered by artificial intelligence and machine learning, to help advance the inaugural project, which looks to improve equity and reduce cost in cancer treatments. 

Key Points: 
  • As a founding member, SOPHiA GENETICS will help drive the success of CancerX, collaborating to set priorities and practices that will harness the power of innovation to further cancer care and research.
  • "As a leader in data-driven medicine, SOPHiA GENETICS is eager to join forces with CancerX and its partners that will lend their expertise towards expediting cancer research and innovation in the U.S.," said Kevin Puylaert, Vice President, Business Development & Marketing for SOPHiA GENETICS.
  • We look forward to leveraging the collective intelligence that our platform creates to help progress cancer research as we embark on our work with CancerX."
  • The SOPHiA DDM™ Platform will not only help bring CancerX partner data together but will accelerate research work to help facilitate breakthroughs.

Slope, Leader in Modernizing Clinical Trial Execution, Joins CancerX as Founding Member

Retrieved on: 
Friday, June 2, 2023
White House, Office of the National Coordinator for Health Information Technology, Partnership, Office of the Assistant Secretary for Health, Life, Yale Physician Associate Program, Clinical trial, Cancer, White House Conference on Aging, H. Lee Moffitt Cancer Center & Research Institute, Research, Assistant, Cancer Moonshot, Incidence, Slope, ONC, Patient, Digital, Death, News, Dime, Bankruptcy, Pharmaceutical industry, Vaccine

RICHMOND, Va., June 2, 2023 /PRNewswire/ -- Slope, the industry-leading provider of a clinical trial execution platform focusing on clinical inventory and sample management, announced today its role as a founding member of CancerX. This public-private partnership, which is a part of The White House's reignited national Cancer Moonshot, aims to revolutionize cancer research and treatment through the power of digital innovation. CancerX is co-hosted by the Moffitt Cancer Center and the Digital Medicine Society (DiMe), in collaboration with the Office for the National Coordinator for Health Information Technology (ONC) and Office of the Assistant Secretary for Health (OASH).

Key Points: 
  • RICHMOND, Va., June 2, 2023 /PRNewswire/ -- Slope , the industry-leading provider of a clinical trial execution platform focusing on clinical inventory and sample management, announced today its role as a founding member of CancerX .
  • Slope will leverage its expertise in complex oncology clinical trials and tech innovation to accelerate treatments.
  • As a founding member of CancerX, Slope will leverage its expertise in complex oncology clinical trials and technological innovation to accelerate treatments and contribute to the ambitious goal of reducing cancer deaths by 50% over the next 25 years.
  • "We are honored to support CancerX's mission to bring innovation to the fight against cancer," said Hope Meely, Chief Clinical Officer at Slope.

Folia Health joins the Cancer Moonshot’s CancerX Public-Private Partnership as a Founding Member

Retrieved on: 
Friday, June 2, 2023
Toxicity, Office of the National Coordinator for Health Information Technology, Partnership, Cancer, Hope, Research, Dime, Assistant, Organization, ONC, Patient, Ecosystem, H. Lee Moffitt Cancer Center & Research Institute, Death, Office of the Assistant Secretary for Health, Caregiver, Pharmaceutical industry, Mobile phone, Medical imaging, Health

Folia Health will join a number of leading organizations in this public-private, pre-competitive evidence generation initiative to advance digital innovation in cancer care.

Key Points: 
  • Folia Health will join a number of leading organizations in this public-private, pre-competitive evidence generation initiative to advance digital innovation in cancer care.
  • said Nell Meosky Luo, Founder and CEO of Folia Health.
  • "This type of collaborative, pre-competitive environment is critical to solving problems that matter to people affected by cancer, and reducing the incredible financial burden of cancer care.
  • Tens of thousands of users use Folia Health to track their health observations, and a number of them manage their (or a loved one’s) cancer, cancer survivorship, and other comorbidities.

Thyme Care Joins CancerX Innovation Accelerator as Founding Member to Ignite Cancer Moonshot

Retrieved on: 
Friday, June 2, 2023
White House, Office of the National Coordinator for Health Information Technology, Partnership, Office of the Assistant Secretary for Health, Life, Digital, Face, West Midlands CARE Team, Cancer, Quality of life, H. Lee Moffitt Cancer Center & Research Institute, White House Medical Unit, Assistant, Organization, Incidence, ONC, Patient, Risk, Nursing, Diagnosis, Multi, Longevity, Transport, Oncology, Death, Dime, Cancer Moonshot

As a founding member, Thyme Care will help set the strategic direction of the initiative and collaborate on ways to achieve the goals of Cancer Moonshot.

Key Points: 
  • As a founding member, Thyme Care will help set the strategic direction of the initiative and collaborate on ways to achieve the goals of Cancer Moonshot.
  • Cancer Moonshot aims to slash the cancer death rate in half over the next 25 years .
  • It's one of the many reasons why we established Thyme Care," said Bobby Green, co-founder, chief medical officer, and president of Thyme Care.
  • Built by a team of oncology industry veterans , Thyme Care guides patients through their cancer journey by providing comprehensive cancer care navigation and support.

ORIEN Member Presentations at 2023 ASCO Demonstrate Unique Value of Aster Insights' Data

Retrieved on: 
Tuesday, May 30, 2023
Roswell Park Comprehensive Cancer Center, Focused Ultrasound Foundation, Partnership, Doctor of Pharmacy, University, CRC, Aster, American Society of Clinical Oncology, Cancer, Development of the human body, Research, Roswell Park, RNA, Immunotherapy, Doctor of Philosophy, AVATAR, ASCO, DO, Patient, Data, Sequence, Annual general meeting, Inherit, Genetic heterogeneity, Listeria monocytogenes non-coding RNA, H. Lee Moffitt Cancer Center & Research Institute, WES, Health, Society, Compugen (company), WTS, Pharmaceutical industry, Medical imaging, Vaccine

TAMPA, Fla., May 30, 2023 /PRNewswire/ -- Aster Insights ("the Company"), the leading provider of technology-enabled data and analytics solutions for oncology discovery, today announced its participation as a research partner at the American Society of Clinical Oncology (ASCO) Annual Meeting, June 2-6, 2023 in Chicago, IL. An oral presentation and three posters will be presented at this year's ASCO meeting, utilizing the lifetime patient-consented longitudinal clinicogenomic data from the Company's Oncology Research Information Exchange Network® (ORIEN) AVATAR program. These presentations highlight the research partnerships and collaboration of Aster Insights and 18 premier cancer centers that comprise ORIEN.

Key Points: 
  • An oral presentation and three posters will be presented at this year's ASCO meeting, utilizing the lifetime patient-consented longitudinal clinicogenomic data from the Company's Oncology Research Information Exchange Network® ( ORIEN ) AVATAR program.
  • These presentations highlight the research partnerships and collaboration of Aster Insights and 18 premier cancer centers that comprise ORIEN.
  • "We are thrilled to be selected for these diverse presentations at ASCO that showcase the incredible work of ORIEN and Aster Insights," said Jill Kolesar, PharmD, Director of the Precision Medicine Center at the Markey Cancer Center and Chair of the ORIEN Executive Advisory Committee.
  • For more information about our ASCO presentations, please contact Aster Insights at: [email protected]